SCHEMBL7708478

SCHEMBL7708478

CC1Oc2ccc(C(Cc3ccc(Cl)c(Cl)c3)NC(=O)OC(C)(C)C)cc2NC1=S.CC1Oc2ccc(C(Cc3ccc(Cl)cc3)NC(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.35
S1PR3 Q99500 1/20 0.34
GAA P10253 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
BCL2 P10415 1/20 0.33
CACNA1B Q00975 1/20 0.33
CTSL P07711 1/20 0.33
ALDH1A1 P00352 3/20 0.32
LMNA P02545 2/20 0.32
PKM P14618 2/20 0.32
HPGD P15428 2/20 0.32
TSHR P16473 2/20 0.32
HTT P42858 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
AGTR1 P30556 1/20 0.32
RAB9A P51151 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7091267 0.97 HSD17B10 (0.33) HSD17B10S1PR3CTSLALDH1A1LMNA
SCHEMBL7092472 0.95 HSD17B10 (0.37) HSD17B10GAAPPARGPPARACACNA1B
SCHEMBL7708475 0.90
SCHEMBL7708252 0.88 CTSL (0.45) HSD17B10CTSLALDH1A1LMNAPKM
SCHEMBL7713423 0.88 PARP1 (0.41) HSD17B10CTSLALDH1A1TSHRTP53
SCHEMBL7095640 0.88 ALDH1A1 (0.37) HSD17B10GAAPPARGPPARAALDH1A1
SCHEMBL7087725 0.87 CTSS (0.41) HSD17B10ALDH1A1LMNAPKMHPGD
SCHEMBL7704943 0.87 ALDH1A1 (0.43) HSD17B10CTSLALDH1A1LMNAPKM
SCHEMBL7093383 0.86 MC4R (0.41) HSD17B10S1PR3GAACTSLALDH1A1
SCHEMBL7094044 0.86 SMN1; SMN2 (0.40) HSD17B10PPARGPPARACACNA1BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed